Anthos Therapeutics
Anthos Therapeutics: Advancing CVM disease care through innovative, validated biopharmaceutical therapies.
Founded
2018Anthos Therapeutics: Advancing CVM disease care through innovative, validated biopharmaceutical therapies.
Founded with a mission to advance care for individuals with cardiovascular and metabolic (CVM) diseases, Anthos Therapeutics is a clinical-stage biopharmaceutical company. The company focuses on developing and commercializing innovative therapies that are both genetically and pharmacologically validated. Their primary product, Abelacimab, targets Factor XI inhibition, aiming to address significant unmet needs in anticoagulation therapy. Anthos Therapeutics is dedicated to providing life-preserving treatments for high-risk CVM patients.
Notable figures associated with Anthos Therapeutics include experienced leaders in biopharmaceuticals and investors committed to advancing cardiovascular health. The company has garnered attention for its potential breakthrough in anticoagulants, as highlighted by a Wall Street Journal article. Through its pioneering work on Abelacimab, Anthos Therapeutics has made significant strides in addressing one of cardiology’s toughest challenges, positioning itself as a key player in the biopharmaceutical landscape.
Companies similar to Anthos Therapeutics include eXIthera Pharmaceuticals, Antios Therapeutics, Astria Therapeutics and Angiex.
Anthos Therapeutics was founded in 2018.
Anthos Therapeutics' headquarters is located in Cambridge, MA, US.
Anthos Therapeutics' most recent funding round was for $250M (USD) in February 2019.
As of Feb 27, 2019, Anthos Therapeutics has disclosed funding of $250M (USD). Undisclosed round amounts are excluded.
Anthos Therapeutics has 33 employees as of Feb 4, 2024.
Angiex
angiex.com
